|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500115507 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-26 16:31:41 |
|
注册时间: Date of Registration: |
2025-12-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于旅程地图的慢性阻塞性肺疾病患者健康管理方案的构建与应用 |
|
Public title: |
Development and Application of a Journey Map-Based Health Management Program for Patients with Chronic Obstructive Pulmonary Disease |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于旅程地图的慢性阻塞性肺疾病患者健康管理方案的构建与应用 |
|
Scientific title: |
Development and Application of a Journey Map-Based Health Management Program for Patients with Chronic Obstructive Pulmonary Disease |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈晟茜 |
研究负责人: |
陈晟茜 |
|
Applicant: |
Chen Shengqian |
Study leader: |
Chen Shengqian |
|
申请注册联系人电话: Applicant telephone: |
+86 180 0588 1510 |
研究负责人电话:
Study leader's |
+86 180 0588 1510 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18005881510@189.cn |
研究负责人电子邮件: Study leader's E-mail: |
18005881510@189.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市钱塘区9号大街9号 |
研究负责人通讯地址: |
浙江省杭州市钱塘区9号大街9号 |
|
Applicant address: |
No. 9, 9th Avenue, Qiantang District, Hangzhou City, Zhejiang Province |
Study leader's address: |
No. 9, 9th Avenue, Qiantang District, Hangzhou City, Zhejiang Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江中医药大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Zhejiang Chinese Medical University |
||
|
研究负责人所在单位: |
浙江中医药大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Zhejiang Chinese Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-KLS-948-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江中医药大学附属第一医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Zhejiang University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-05 00:00:00 | ||
|
伦理委员会联系人: |
夏冰 |
||
|
Contact Name of the ethic committee: |
Xia Bing |
||
|
伦理委员会联系地址: |
浙江省杭州市钱塘区9号大街9号 |
||
|
Contact Address of the ethic committee: |
No. 9, 9th Avenue, Qiantang District, Hangzhou City, Zhejiang Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 136 0051 9473 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
allan.xia.1989@163.com |
|
研究实施负责(组长)单位: |
浙江中医药大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Zhejiang Chinese Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市钱塘区9号大街9号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 9, 9th Avenue, Qiantang District, Hangzhou City, Zhejiang Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
COPD(慢阻肺) |
||||||||||||||||||||||
|
Target disease: |
COPD (Chronic Obstructive Pulmonary Disease) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.本研究旨在基于旅程地图构建COPD(慢阻肺)患者健康管理,通过系统化梳理患者从疾病诊断、急性加重管理、稳定期维持到康复支持的全过程,明确各阶段的关键节点及医疗需求。 2.基于旅程地图,优化健康管理流程,提升患者自我管理能力及生活质量,同时为医疗机构提供科学化、个性化的慢性病管理工具,推动COPD患者全程化健康管理模式的实践与应用。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. This study aims to establish a health management framework for COPD (Chronic Obstructive Pulmonary Disease) patients based on journey mapping. By systematically mapping the entire patient journey—from disease diagnosis, acute exacerbation management, stable-phase maintenance, to rehabilitation support—it identifies key milestones and healthcare needs at each stage. 2. Leveraging the journey map, the study optimizes health management processes to enhance patients' self-management capabilities and quality of life. Simultaneously, it provides healthcare institutions with scientific, personalized chronic disease management tools, advancing the implementation and application of a comprehensive health management model for COPD patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合《COPD诊治指南》诊断标准;2.年龄≥18周岁;3.有智能手机并会使用微信;4.知情同意,自愿参加本研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meets the diagnostic criteria outlined in the COPD Diagnosis and Treatment Guidelines; 2.Age>= 18 years; 3. Possesses a smartphone and is proficient in using WeChat; 4.Provides informed consent and voluntarily participates in this study. |
||||||||||||||||||||||
|
排除标准: |
1.合并肺结核、气胸、肺癌等其他严重肺部疾病者;2.患有严重的心、脑、肝、肾疾病的患者;3.合并神经及精神疾病的患者;4.有严重听力、言语功能障碍的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with concurrent severe pulmonary diseases such as tuberculosis, pneumothorax, or lung cancer; 2. Patients with severe cardiac, cerebral, hepatic, or renal diseases; 3. Patients with concurrent neurological or psychiatric disorders; 4. Patients with severe hearing or speech impairments. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究属于实验性研究,采用随机数字表法,根据入院顺序用SPSS生成98个数字,然后进行98个数字随机分号,将分号再进行随机分组,分为对照组和试验组,连续选取某三甲医院呼吸科符合纳入排除标准的COPD住院患者作为本次研究对象。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study is an experimental investigation employing a random number table method. Using SPSS, 98 random numbers were generated based on admission sequence. These numbers were then randomly assigned to create two groups: a control group and an experimental group. Inpatient COPD patients meeting the inclusion and exclusion criteria from the respiratory department of a tertiary hospital were consecutively selected as study subjects. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
建立数据库,确定变量后,将数据录入SPSS数据库,此过程由研究者及另外一人分别录入试验结果,然后交换录入结果,分别进行审核。所有数据应用SPSS25.0进行统计分析。计量资料以(±s)表示,组内比较采用配对t检验,组间比较采用独立t检验。计数资料以[n(%)]表示,比较采用x2检验。以P<0.05为差异有统计学意义。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
After establishing the database and defining variables, data were entered into the SPSS database. This process involved two researchers independently entering trial results, followed by cross-checking and reviewing each other's entries. All data were statistically analyzed using SPSS 25.0. Quantitative data are expressed as mean ± standard deviation (+/-s). Intra-group comparisons were performed using paired t-tests, while inter-group comparisons employed independent t-tests. Categorical data are presented as [n (%)], with comparisons conducted using chi-square (χ2) tests. A P value < 0.05 was considered statistically significant. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |